This site is not optimized for mobile devices. For the best mobile experience we suggest you download our mobile app!
Download on App Store App Store Icon App Store Google Play Store Icon Google Play

Cytomegalovirus (CMV)

Cytomegalovirus (CMV) infections

Diagnosis and treatment

Diagnosis:
Retinitis: typical retinal lesions at ophthalmological examination AND response to therapy. Identification of CMV-DNA by NAT in of aqueous and vitreous humor optional
Esophagitis/colitis: endoscopic presence of ulcerations AND typical histopathological picture (cellular / nuclear inclusion bodies) with identification of CMV antigens
Encephalitis/polyradiculomyelitis: clinical appearance AND Identification of CMV-DNA by NAT in CSF
Identification of CMV-DNA in blood supportive, but not diagnostic of end-organ disease

Notes on treatment:
monitor renal function and adjust drug dose in renal impairment. See also Anti-infective/ART interaction table

  Drug / Dose Comments
Retinitis, Immediate sight-threatening lesions  ganciclovir
5 mg/kg bid iv
3 weeks, then secondary prophylaxis
OR
foscarnet
90 mg/kg bid iv
Foscarnet used as alternative therapy if toxicity or resistance to ganciclovir. Most experts would add intravitreal injections of ganciclovir (2 mg) or foscarnet (2.4 mg) for 1-4 doses over 7-10 days in combination with systemic CMV treatment
Retinitis, small peripheral retinal lesions  valganciclovir
900 mg bid po (with food)
2-3 weeks, then secondary prophylaxis
OR
ganciclovir
5 mg/kg bid iv
OR
foscarnet
90 mg/kg bid iv
 If adverse reactions or ineligibility to ganciclovir/valganciclovir
Esophagitis/Colitis   ganciclovir
5 mg/kg bid iv
3-6 weeks, until symptoms resolved, then secondary prophylaxis (switch to oral valganciclovir once tolerated)
OR
foscarnet
90 mg/kg bid iv
 
OR
valganciclovir
900 mg bid po (with food)
In milder disease if oral treatment tolerated
Encephalitis/Myelitis

ganciclovir
5 mg/kg bid iv 

foscarnet
90 mg/kg bid iv

Treat until symptoms resolved with clearance of CMV-DNA in CSF, then secondary prophylaxis

Some experts recommend ganciclovir combined with foscarnet especially in progressive or relapsing cases

Cidofovir (+ probenecid) may be considered as a therapeutic option for patients unable to tolerate the other treatments listed 

Secondary Prophylaxis/ Maintenance Therapy

Cytomegalovirus (CMV) Retinitis

Stop: Inactive lesions treated for at least 3 months AND CD4 count > 100 cells/µL with HIV-VL undetectable over 3 months

Regimens listed are alternatives

Drug / Dose
valganciclovir (preferred regimen)
900 mg qd po (with food)
OR
ganciclovir
5 mg/kg qd iv (x 5 days/ week)
OR
foscarnet
90-120 mg/kg qd iv (x 5 days/ week)